SPIB is a novel prognostic factor in diffuse large B‐cell lymphoma that mediates apoptosis via the PI3K‐AKT pathway

Although the clinical outcomes of diffuse large B‐cell lymphoma (DLBCL) have improved in the immunochemotherapy era, approximately one‐third of patients develop intractable disease. To improve clinical outcomes for these patients, it is important to identify those with poor prognosis prior to initia...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Sci
Auteurs principaux: Takagi, Yusuke, Shimada, Kazuyuki, Shimada, Satoko, Sakamoto, Akihiko, Naoe, Tomoki, Nakamura, Shigeo, Hayakawa, Fumihiko, Tomita, Akihiro, Kiyoi, Hitoshi
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2016
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5021043/
https://ncbi.nlm.nih.gov/pubmed/27348272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13001
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires